SMS Pharmaceuticals Ltd’s Volatile Week: -1.49% Amid New Highs and Sharp Declines

9 March 2026: Valuation Shifts Signal Changing Price Attractiveness

SMS Pharmaceuticals Ltd began the week trading at Rs.382.20, up 1.73% on the day, while the Sensex declined 1.91%. The company’s valuation grade improved from very expensive to expensive, reflecting a subtle enhancement in price attractiveness. The price-to-earnings ratio stood at 39.33, down from previous levels, and the stock’s price-to-book value and EV/EBITDA ratios positioned it competitively within the Pharmaceuticals & Biotechnology sector.

Despite a slight daily decline of 1.47% reported on 9 March, the stock’s relative performance and improved valuation metrics suggested a nuanced outlook. SMS Pharmaceuticals’ strong long-term returns, including a 91.94% gain over one year and a 447.28% gain over three years, underpin its robust growth trajectory.

10 March 2026: New 52-Week High and Intraday Peak Amid Strong Momentum

The stock surged sharply on 10 March, closing at Rs.420.20, a 9.94% gain for the day, significantly outperforming the Sensex’s 1.30% rise. Intraday, SMS Pharmaceuticals touched a new 52-week high of Rs.408.5 and an all-time high of Rs.410, marking a 7.8% intraday surge. This rally was supported by strong technical indicators, including trading above all key moving averages and bullish MACD signals on weekly and monthly charts.

Despite the broader market’s mixed performance and a three-week losing streak for the Sensex, SMS Pharmaceuticals demonstrated resilience and strong buying interest. The stock’s one-year return exceeded 112%, far outpacing the Sensex’s 5.32% gain, highlighting its sector leadership.

11 March 2026: Fresh 52-Week High at Rs.433.8 Amid Mixed Market Conditions

On 11 March, SMS Pharmaceuticals reached a new 52-week high of Rs.433.8, extending its three-day winning streak with a cumulative return of 12.47%. Despite this, the stock closed marginally down 1.75% at Rs.412.85, slightly underperforming its sector. The broader market was weaker, with the Sensex falling 1.36% amid bearish technical signals.

Technical indicators remained predominantly bullish, with positive MACD and Bollinger Bands readings on weekly and monthly charts. The stock continued to trade above all major moving averages, signalling sustained upward momentum despite short-term volatility. SMS Pharmaceuticals’ one-year gain of 117.24% contrasted sharply with the Sensex’s 4.63% rise, underscoring its relative strength.

12 March 2026: Price Pressure Begins as Stock Declines Amid Market Weakness

On 12 March, the stock price declined further to Rs.402.95, down 2.40%, continuing the short-term correction. The Sensex also fell 0.66%, reflecting broader market weakness. SMS Pharmaceuticals remained above its 20-day, 50-day, 100-day, and 200-day moving averages, though the decline below the 5-day average indicated emerging short-term selling pressure.

Despite the pullback, technical signals such as bullish MACD and Bollinger Bands persisted, suggesting the correction was part of a broader consolidation rather than a reversal. The stock’s long-term performance metrics remained strong, with year-to-date gains of 21.07% and three-year returns exceeding 449%.

13 March 2026: Intraday Low and Sharp Decline Amid Price Pressure

Shares of SMS Pharmaceuticals Ltd faced significant selling pressure on 13 March, hitting an intraday low of Rs.374.45 and closing down 8.15% at Rs.370.10. This marked the third consecutive day of decline, with a cumulative loss of 10.28% over this period. The stock underperformed both its sector and the Sensex, which fell 2.29% on the day.

Despite the sharp drop, the stock remained above its 20-day, 50-day, 100-day, and 200-day moving averages, though it traded below the 5-day average, indicating short-term weakness. The broader market environment was subdued, with multiple indices hitting new lows and the Sensex exhibiting a bearish technical setup.

Technical indicators presented a mixed picture: bullish MACD and Bollinger Bands contrasted with mildly bearish KST readings and neutral RSI signals. The On-Balance Volume remained bullish on weekly and monthly charts, suggesting underlying volume support despite recent price declines.

Weekly Price Performance Comparison

Key Takeaways

Positive Signals: SMS Pharmaceuticals demonstrated strong relative strength versus the Sensex, outperforming the benchmark by over 3% despite a weekly decline. The stock hit multiple new 52-week highs, reflecting sustained momentum and investor interest. Technical indicators such as MACD and Bollinger Bands largely supported a bullish trend, and the company’s valuation grade improved, signalling enhanced price attractiveness.

Cautionary Signals: The sharp decline on 13 March and three-day losing streak highlight short-term volatility and profit-taking pressures. The stock’s elevated valuation multiples remain a consideration, and some technical indicators such as the KST and OBV showed mixed or mildly bearish signals. Broader market weakness and bearish Sensex trends may continue to weigh on near-term performance.

Conclusion

SMS Pharmaceuticals Ltd’s week was marked by a volatile price journey, with impressive gains early in the week culminating in new 52-week highs, followed by a sharp correction in the final sessions. Despite closing the week down 1.49%, the stock outperformed the Sensex’s 4.87% decline, underscoring its relative resilience amid a challenging market backdrop. The company’s improved valuation grade and strong long-term returns provide a foundation of strength, while recent price pressure signals the need for cautious monitoring of short-term trends. Overall, SMS Pharmaceuticals remains a notable player within the Pharmaceuticals & Biotechnology sector, balancing robust growth with episodic volatility.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →